Etanercept in erythema nodosum leprosum

One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the...

Full description

Saved in:
Bibliographic Details
Published inAnais brasileiros de dermatología Vol. 92; no. 4; pp. 575 - 577
Main Authors Santos, Julia Rocha Silva, Vendramini, Dâmia Leal, Nery, José Augusto da Costa, Avelleira, João Carlos Regazzi
Format Journal Article
LanguageEnglish
Portuguese
Published Brazil Sociedade Brasileira de Dermatologia 01.07.2017
Subjects
Adult
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Communication
DERMATOLOGY
Erythema nodosum
Erythema Nodosum - drug therapy
Etanercept - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
Leprosy
Leprosy, Lepromatous - drug therapy
Male
Prednisone - therapeutic use
Thalidomide - therapeutic use
Tumor necrosis factor-alpha
Leprosy
Erythema nodosum
Tumor necrosis factor-alpha
Online AccessGet full text

Cover

Abstract One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
AbstractList One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or erythema nodosum leprosum, during treatment, and this reaction can remain in a recurrent form after being released from the hospital, requiring the use of thalidomide and/or prednisone for long periods of time, in turn increasing the risk of side effects. Two reports of the use of antiTNF to treat erythema nodosum leprosum were found in the literature. A good response was found after an assay with infliximab and etanercept. This study reports on a patient with lepromatous leprosy and recurrent reaction, controlled by using etanercept and a 10-month follow-up, with the interruption of thalidomide and the maintenance of prednisone at 10 mg/day.
Author Vendramini, Dâmia Leal
Avelleira, João Carlos Regazzi
Nery, José Augusto da Costa
Santos, Julia Rocha Silva
AuthorAffiliation 3 Dermatology Service, Hospital Federal da Lagoa - Rio de Janeiro (RJ), Brazil
2 Leprosy Laboratory, Fundação Oswaldo Cruz, Fiocruz - Rio de Janeiro (RJ), Brazil
1 Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil
AuthorAffiliation_xml – name: 2 Leprosy Laboratory, Fundação Oswaldo Cruz, Fiocruz - Rio de Janeiro (RJ), Brazil
– name: 3 Dermatology Service, Hospital Federal da Lagoa - Rio de Janeiro (RJ), Brazil
– name: 1 Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil
– name: Santa Casa de Misericórdia do Rio de Janeiro
– name: Fiocruz
– name: Hospital Federal da Lagoa
Author_xml – sequence: 1
  givenname: Julia Rocha Silva
  surname: Santos
  fullname: Santos, Julia Rocha Silva
  organization: Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil
– sequence: 2
  givenname: Dâmia Leal
  surname: Vendramini
  fullname: Vendramini, Dâmia Leal
  organization: Professor Rubem David Azulay Dermatology Institute, Santa Casa de Misericórdia do Rio de Janeiro (DPRDA-SCMRJ) - Rio de Janeiro (RJ), Brazil
– sequence: 3
  givenname: José Augusto da Costa
  surname: Nery
  fullname: Nery, José Augusto da Costa
  organization: Leprosy Laboratory, Fundação Oswaldo Cruz, Fiocruz - Rio de Janeiro (RJ), Brazil
– sequence: 4
  givenname: João Carlos Regazzi
  surname: Avelleira
  fullname: Avelleira, João Carlos Regazzi
  organization: Dermatology Service, Hospital Federal da Lagoa - Rio de Janeiro (RJ), Brazil
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28954119$$D View this record in MEDLINE/PubMed
BookMark eNpVkU9v1DAQxS1URLeFjwDaG1x2mfG_xBckVLWlUiUOwNly7HGbVRIvToLUb4_Dblf0ZGtm3pvR712wsyENxNh7hC0qA59dE7AGvZG1xC0HrJSs8BVbnYpnbAVCqw0oo8_ZxTjuALg0lXnDznltlEQ0K_bxenIDZU_7ad0Oa8pP0yP1bj2kkMa5X3e0z8vnLXsdXTfSu-N7yX7dXP-8-ra5_357d_X1fuMV6qksdlIqwdFzZxSgl0JJ0WDFjYxcm4hN41TtGhNicME3hisiEFFAbAJoccnuDr4huZ3d57Z3-ckm19p_hZQfrMtT6zuyFDWEygmNtZGak_HGhyg5qkgYuChe24PX6Fvqkt2lOQ_lePtjAWMXMAs4AJAAqlJF8OUg2M9NT8HTMGXXvbjiZWdoH-1D-mOVMkpjVQw-HQ1y-j3TONm-HT11XWGc5tGikbIQwaouo-ow6gvfMVM8rUGwS8L2mLBdwrTPCRfdh_9vPKmeIxV_AV13oSQ
CitedBy_id crossref_primary_10_1111_dth_15125
crossref_primary_10_25259_IJDVL_726_20
crossref_primary_10_3389_fmed_2023_1239775
crossref_primary_10_1016_j_abd_2020_08_032
crossref_primary_10_1016_j_actatropica_2018_02_026
crossref_primary_10_3389_fmed_2022_879527
crossref_primary_10_1016_j_eimc_2019_09_003
crossref_primary_10_1093_ofid_ofaa060
crossref_primary_10_1590_0037_8682_0454_2019
crossref_primary_10_4269_ajtmh_19_0616
crossref_primary_10_1016_j_eimce_2020_03_001
Cites_doi 10.1056/NEJMc052955
10.1093/cid/ciq213
10.1136/ard.55.11.833
10.1128/IAI.60.4.1441-1446.1992
10.1136/gut.50.2.196
ContentType Journal Article
Copyright This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright_xml – notice: This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
DBID CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7X8
5PM
GPN
DOA
DOI 10.1590/abd1806-4841.20175471
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
SciELO
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
MEDLINE - Academic
DatabaseTitleList

MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: Open Access: DOAJ - Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1806-4841
0365-0596
EndPage 577
ExternalDocumentID oai_doaj_org_article_ef60d7a36189462e9c9cdf4215fe1d23
S0365_05962017000400575
10_1590_abd1806_4841_20175471
28954119
Genre Journal Article
Case Reports
GroupedDBID 0SF
2WC
53G
5GY
5VS
6J9
AAEDW
AALRI
AAXUO
ABXHO
ACGFO
ACLIJ
ADBBV
ADRAZ
ADVLN
AENEX
AITUG
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
APOWU
AZFZN
BAWUL
BCNDV
C1A
CGR
CS3
CUY
CVF
DIK
E3Z
EBS
ECM
EIF
EJD
F5P
FDB
GROUPED_DOAJ
GX1
HYE
IPNFZ
KQ8
M41
M48
M~E
NCXOZ
NPM
OK1
P2P
PGMZT
RIG
RNS
ROL
RPM
RSC
SCD
XSB
AAYXX
CITATION
7X8
5PM
GPN
ID FETCH-LOGICAL-c516t-48a445321c2a9501c43543b17294f269f1bba58ab9dfdadcb925ee03f30fbd063
IEDL.DBID RPM
ISSN 0365-0596
1806-4841
IngestDate Tue Oct 22 14:57:45 EDT 2024
Fri Oct 18 21:13:16 EDT 2024
Tue Sep 17 21:24:11 EDT 2024
Thu Aug 15 23:44:36 EDT 2024
Fri Aug 23 01:42:46 EDT 2024
Sat Sep 28 08:02:08 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Leprosy
Erythema nodosum
Tumor necrosis factor-alpha
Language English
Portuguese
License This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivative License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium provided the original work is properly cited and the work is not changed in any way.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. http://creativecommons.org/licenses/by-nc/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c516t-48a445321c2a9501c43543b17294f269f1bba58ab9dfdadcb925ee03f30fbd063
Notes ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5595617/
PMID 28954119
PQID 1944435178
PQPubID 23479
PageCount 3
ParticipantIDs doaj_primary_oai_doaj_org_article_ef60d7a36189462e9c9cdf4215fe1d23
scielo_journals_S0365_05962017000400575
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5595617
proquest_miscellaneous_1944435178
crossref_primary_10_1590_abd1806_4841_20175471
pubmed_primary_28954119
PublicationCentury 2000
PublicationDate 2017-07-01
PublicationDateYYYYMMDD 2017-07-01
PublicationDate_xml – month: 07
  year: 2017
  text: 2017-07-01
  day: 01
PublicationDecade 2010
PublicationPlace Brazil
PublicationPlace_xml – name: Brazil
PublicationTitle Anais brasileiros de dermatología
PublicationTitleAlternate An Bras Dermatol
PublicationYear 2017
Publisher Sociedade Brasileira de Dermatologia
Publisher_xml – name: Sociedade Brasileira de Dermatologia
References 8976641 - Ann Rheum Dis. 1996 Nov;55(11):833-6
11788559 - Gut. 2002 Feb;50(2):196-200
7500827 - Lepr Rev. 1995 Sep;66(3):261-3
16914716 - N Engl J Med. 2006 Aug 17;355(7):739
21292656 - Clin Infect Dis. 2011 Mar 1;52(5):e133-5
2015700 - Clin Exp Immunol. 1991 Apr;84(1):103-8
1548069 - Infect Immun. 1992 Apr;60(4):1441-6
Barnes PF (ref3) 1992; 60
Rigoni ACM (ref5) 2001; 76
Bauditz J (ref6) 2002; 50
Ramien ML (ref9) 2011; 52
Sarno EN (ref2) 1991; 84
Huizinga TW (ref4) 1996; 55
Faber WR (ref8) 2006; 355
Talhari S (ref1) 2015
Talhari S (ref7) 1995; 66
Barnes, PF; Chatterjee, D; Brennan, PJ; Rea, TH; Modlin, RL 1992; 60
Ramien, ML; Wong, A; Keystone, JS 2011; 52
Huizinga, TW; Dijkmans, BA; van der Velde, EA; van de Pouw Kraan, TC; Verweij, CL; Breedveld, FC 1996; 55
Talhari, S; Orsi, AT; Talhari, AC; Souza, FH; Ferreira, LC 1995; 66
Rigoni, ACM; Carneiro, SCS 2001; 76
Talhari, S; Penna, GO; Gonçalves, HS; Oliveira, MLW 2015
Sarno, EN; Grau, GE; Vieira, LM; Nery, JA 1991; 84
Bauditz, J; Wedel, S; Lochs, H 2002; 50
Faber, WR; Jensema, AJ; Goldschmidt, WF 2006; 355
References_xml – volume: 355
  start-page: 739
  year: 2006
  ident: ref8
  article-title: Treatment of recurrent erythema nodosum leprosum with infliximab
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc052955
  contributor:
    fullname: Faber WR
– year: 2015
  ident: ref1
  contributor:
    fullname: Talhari S
– volume: 52
  start-page: e133
  year: 2011
  ident: ref9
  article-title: Severe refractory erythema nodosum successfully treated with the tumor necrosis factor inhibitor etanercept
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciq213
  contributor:
    fullname: Ramien ML
– volume: 84
  start-page: 103
  year: 1991
  ident: ref2
  article-title: Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Sarno EN
– volume: 76
  start-page: 39
  year: 2001
  ident: ref5
  article-title: Estudo aberto com pentoxifilina em pacientes com psoríase
  publication-title: An Bras Dermatol
  contributor:
    fullname: Rigoni ACM
– volume: 66
  start-page: 261
  year: 1995
  ident: ref7
  article-title: Pentoxifiline may be useful in the treatment of type 2 leprosy reaction
  publication-title: Lepr Rev
  contributor:
    fullname: Talhari S
– volume: 55
  start-page: 833
  year: 1996
  ident: ref4
  article-title: An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
  publication-title: Ann Rheum Dis
  doi: 10.1136/ard.55.11.833
  contributor:
    fullname: Huizinga TW
– volume: 60
  start-page: 1441
  year: 1992
  ident: ref3
  article-title: Tumor necrosis factor production in patients with leprosy
  publication-title: Infect Immun
  doi: 10.1128/IAI.60.4.1441-1446.1992
  contributor:
    fullname: Barnes PF
– volume: 50
  start-page: 196
  year: 2002
  ident: ref6
  article-title: Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease
  publication-title: Gut
  doi: 10.1136/gut.50.2.196
  contributor:
    fullname: Bauditz J
– volume: 66
  start-page: 261
  year: 1995
  end-page: 263
  article-title: Pentoxifiline may be useful in the treatment of type 2 leprosy reaction
  publication-title: Lepr Rev
  contributor:
    fullname: Talhari, S; Orsi, AT; Talhari, AC; Souza, FH; Ferreira, LC
– year: 2015
  publication-title: Hanseníase
  contributor:
    fullname: Talhari, S; Penna, GO; Gonçalves, HS; Oliveira, MLW
– volume: 76
  start-page: 39
  year: 2001
  end-page: 49
  article-title: Estudo aberto com pentoxifilina em pacientes com psoríase
  publication-title: An Bras Dermatol
  contributor:
    fullname: Rigoni, ACM; Carneiro, SCS
– volume: 55
  start-page: 833
  year: 1996
  end-page: 836
  article-title: An open study of pentoxifylline and thalidomide as adjuvant therapy in the treatment of rheumatoid arthritis
  publication-title: Ann Rheum Dis
  contributor:
    fullname: Huizinga, TW; Dijkmans, BA; van der Velde, EA; van de Pouw Kraan, TC; Verweij, CL; Breedveld, FC
– volume: 84
  start-page: 103
  year: 1991
  end-page: 108
  article-title: Serum levels of tumour necrosis factor-alpha and interleukin-1β during leprosy reactional states
  publication-title: Clin Exp Immunol
  contributor:
    fullname: Sarno, EN; Grau, GE; Vieira, LM; Nery, JA
– volume: 60
  start-page: 1441
  year: 1992
  end-page: 1446
  article-title: Tumor necrosis factor production in patients with leprosy
  publication-title: Infect Immun
  contributor:
    fullname: Barnes, PF; Chatterjee, D; Brennan, PJ; Rea, TH; Modlin, RL
– volume: 355
  start-page: 739
  year: 2006
  end-page: 739
  article-title: Treatment of recurrent erythema nodosum leprosum with infliximab
  publication-title: N Engl J Med
  contributor:
    fullname: Faber, WR; Jensema, AJ; Goldschmidt, WF
– volume: 52
  start-page: e133
  year: 2011
  end-page: e135
  article-title: Severe refractory erythema nodosum successfully treated with the tumor necrosis factor inhibitor etanercept
  publication-title: Clin Infect Dis
  contributor:
    fullname: Ramien, ML; Wong, A; Keystone, JS
– volume: 50
  start-page: 196
  year: 2002
  end-page: 200
  article-title: Thalidomide reduces tumour necrosis factor α and interleukin 12 production in patients with chronic active Crohn's disease
  publication-title: Gut
  contributor:
    fullname: Bauditz, J; Wedel, S; Lochs, H
SSID ssj0024979
Score 2.2021275
Snippet One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or...
One of the biggest challenges in treating leprosy is the control of reaction events. Patients with lepromatous leprosy may present reaction type II, or...
SourceID doaj
scielo
pubmedcentral
proquest
crossref
pubmed
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
StartPage 575
SubjectTerms Adult
Anti-Inflammatory Agents, Non-Steroidal - therapeutic use
Communication
DERMATOLOGY
Erythema nodosum
Erythema Nodosum - drug therapy
Etanercept - therapeutic use
Humans
Immunosuppressive Agents - therapeutic use
Leprosy
Leprosy, Lepromatous - drug therapy
Male
Prednisone - therapeutic use
Thalidomide - therapeutic use
Tumor necrosis factor-alpha
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3PS95AEB1EingRq7VNrRKh4Ck1m-xudo5tUUTQixW8LfsTBYlFPw_97zu7m4gfFnrxFpKQZN9sMu-xkzcAX4NUaJBxesXd0PAh2sZ20jSdkug4qVyffxI7v5CnV_zsWly_aPWVasKKPXAB7ihE2frB9JIp5LIL6ND5yClTxcB8V3w-W5zF1Oyyh8VlL9VwpQYz0787AtsjYz1TJKO54kkfUvrkA1vKStm8_1-M83Xh5LuUp-5epqSTTdiYuGT9vYzhPayEcQvWzqfV8m04PCbmVwpX6tuxDg9_skVrPZIUpQlY3wW6N218gKuT418_T5upMULjBJMLenTDueg75jqDomWOOA_vLXER5LGTGJm1Rihj0UdvvLPYiRDaPvZttJ5IyQ6sjvdj-AS1MYPzdK6IuS26IlBIs0prLLMYVKjg2wyM_l38L3TSDYSknpDUCUk9I1nBjwTf88nJvjrvoKDqKaj6f0Gt4GAGX9N0T2sYhNf906NmyDmNlg2qgo8lGM-3Iu0oOGNYwbAUpqVnWT4y3t5kS23SVUQkhwoOS0D19CY_6ss0h3RuUpSshvJHjyju57cY5i6sp4uW6t8vsLp4eAp7xHEWdj9P579wVfNK
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV3da9UwFD-MKeKL-G39ooKwp84mPUmTBxGVjSHMF72wt5BPHVx69e4O3H_vSdrOXdzeSpuS5pecnt8hJ78D8DZKpa1mSCbu-wb75BrHpW24ktojRbmhHBI7_iqPFvjlRJzswCyoMAF4dm1ol-tJLdbL_T-_Lz6Qwb8v1Xt0-866wBQFxqgwR3zkEDGfKr_FszZXzuZD9U9-T_d6Oshz46tZIFhpgSzL71zxVkXU_zom-n9C5e3sv5ZXXdXhfbg3ccz647goHsBOHB7CneNpF_0R7B0QIxwTWurToY7riyLdWg8UotLCrJeR-qaLx7A4PPj--aiZCiY0XjC5oVFYRNFx5rnVomWeuBB2jjiKxsSlTsw5K5R1OqRgg3eaixjbLnVtcoHIyhPYHVZDfAa1tb0P1FakUi5dET4Uy0pnHXM6qljB_gyM-TXqYpgcTxCoZgLVZFDNDGoFnzJ8l42zrHW5sVr_MJOVmJhkG3rbSaY0Sh611z4kJFqSIgu8q-DNDL4hM8h7G4TX6vzMMI1Io2W9quDpOBmXXc2TWUG_NU1b37L9ZDj9WaS2Kd4igtlXsDdOqJkXqPlGrl-YUrwoSxCVnyFR3-c39v4C7uaWY6rvS9jdrM_jKyI0G_e6LNG_bbvswg
  priority: 102
  providerName: Scholars Portal
Title Etanercept in erythema nodosum leprosum
URI https://www.ncbi.nlm.nih.gov/pubmed/28954119
https://search.proquest.com/docview/1944435178
https://pubmed.ncbi.nlm.nih.gov/PMC5595617
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962017000400575&lng=en&tlng=en
https://doaj.org/article/ef60d7a36189462e9c9cdf4215fe1d23
Volume 92
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na9wwEB2SUEovIWmbxvnChUJO3rVsSZaOSUgIhS2FJJCb0Ge7sOsNm80h_z4j2Q5Z0lMvxtjCst-MPW-s0RPAD8-F1JJQfMVtU9AmmMJUXBeV4NJSzHJdmiQ2-cWv7-jPe3a_AWyYC5OK9q2ZjtrZfNRO_6bayoe5HQ91YuPfkwtkwRj2m_EmbKKDDin6ILAnO4G9WL4V15bpp-0wWY61cURgBk0FjakhRk78NEc5YCEZJVFs501sShL-_-Kd78snP8RoNXsbmK52YLtnlPlZd-e7sOHbz_Bx0o-Zf4HTS-R_XflKPm1zv3xOQq15iwkpumE-89g37nyFu6vL24vrol8eobCM8BU-haaU1RWxlZasJBaZD60NMhJJQ8VlIMZoJrSRLjjtrJEV876sQ10G45Ca7MFWu2j9PuRaN9ZhWxbS4ugC8cHMlRttiJFe-AxGAzDqoVPBUDF7QFBVD6qKoKoB1AzOI3yvjaOIdTqwWP5RvSmVD7x0ja45EZLyyksrrQsUSUjwxFV1Bt8H8BU6fRzJQLwWT4-KSErxaUkjMvjWGeO1q8GYGTRrZlq7l_Uz6GdJWLv3qwxOO4Oq_n1-VDfRnVRaqigKDqVPHxLdg__u4xA-xSt1hb9HsLVaPvljpDcrc5J-C-B2QsVJcu0XY8_1cQ
link.rule.ids 230,315,730,783,787,867,888,2109,2228,24332,27938,27939,53806,53808
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VgoBLeRUI5REkpJ6SjRPbiY9t1WqBboVEi3qz_IQV22y13T3Ar2fsJFUXuMAtipPYns_2fKOMPwO8c7wRShCKU9zUGa29znTJVVY2XBiKUa6Nm8QmJ3x8Rj-cs_MNYMNemJi0b_Q0b2cXeTv9FnMrLy_MaMgTG32aHCALRrdfj27BbZyvBR-C9EFiT3QSeyGBK5wu02_cYaIYKW0JvpDRhobgEH0nLs5BELgRjJIgt3PDO0UR_78xzz8TKO8EfzW76ZqOHsCXoVNdRsr3fLXUufn5m97jP_f6IWz1ZDXd64ofwYZrH8PdSf87_gnsHiK17DJj0mmbusWPqAGbthjr4ghPZw7bhBfbcHZ0eHowzvqTFzLDCF-ieRSlrCqJKZVgBTFIqmilkewI6ksuPNFasUZpYb1V1mhRMueKyleF1xZZz1PYbOetew6pUrWx-Czz8dz1Bg2PQTHXShMtXOMSyAeLy8tOYEOGwATRkj1aMqAlB7QS2A-4XD8c9LHjjfniq-ztJZ3nha1VxUkjKC-dMMJYT5HfeEdsWSXwdkBV4nwKP0nQXvPVlSSCUuwtqZsEnnUoX1c1jJIE6jX819qyXoJgRs3uHrwEdruRIvul4kp-DuNUxlOQgpZRXFWRQ7_47zrewL3x6eRYHr8_-bgD98NXu_zil7C5XKzcK2RRS_06zplfkGgVrw
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5BQVUvvB_hGSSknrKJE8exj1C6Ko-tKkGliovlJ6y6za62uwf49YydpNoFTr1FiZXE84093yiTbwDeOsaFEoTiEjdNRhuvM10ylZWcCUMxy7XxJ7HJMTs6pZ_O6rONVl-xaN_o6aidXYza6c9YW7m4MPlQJ5afTA6QBWPYb_KF9flNuIVrtuBDoj7I7IlOZi8UcYUOM_3PO7UocqUt4ZhHU05DgojxEzfoIArMRU1JkNzZiFBRyP9_7PPfIsrbIWbNNsPT-C58HybWVaWcj9YrPTK__9J8vNbM78GdnrSm77oh9-GGax_A7qT_LP8Q9g-RYnYVMum0Td3yV9SCTVvMedHT05nD98KDR3A6Pvx2cJT1HRgyUxO2QhMpSuuqJKZUoi6IQXJFK42kR1BfMuGJ1qrmSgvrrbJGi7J2rqh8VXhtkf08hp123rqnkCrVGItjax_7r3M0PibHTCtNtHDcJTAarC4XndCGDAkKIiZ7xGRATA6IJfA-YHM1OOhkxxPz5Q_Z20w6zwrbqIoRLigrnTDCWE-R53hHbFkl8GZAVuK6Ch9L0F7z9aUkglKcLWl4Ak86pK8eNXhKAs2WD2y9y_YVBDRqd_cAJrDfeYvst4xL-TX4qozdkIKmUdxdkUs_u_YzXsPuyYex_PLx-PNz2As37cqMX8DOarl2L5FMrfSruGz-AGzvGC8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Etanercept+in+erythema+nodosum+leprosum&rft.jtitle=Anais+brasileiros+de+dermatolog%C3%ADa&rft.au=Santos%2C+Julia+Rocha+Silva&rft.au=Vendramini%2C+D%C3%A2mia+Leal&rft.au=Nery%2C+Jos%C3%A9+Augusto+da+Costa&rft.au=Avelleira%2C+Jo%C3%A3o+Carlos+Regazzi&rft.date=2017-07-01&rft.eissn=1806-4841&rft.volume=92&rft.issue=4&rft.spage=575&rft_id=info:doi/10.1590%2Fabd1806-4841.20175471&rft_id=info%3Apmid%2F28954119&rft.externalDocID=28954119
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0365-0596&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0365-0596&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0365-0596&client=summon